Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer:...

Area of Science:

• Oncology
• Clinical Pharmacology
• Gastrointestinal Oncology

Background:

• Metastatic colorectal cancer (MCRC) remains a significant health challenge.
• Oxaliplatin-based chemotherapy regimens are standard first-line treatments for MCRC.
• Bevacizumab, an anti-angiogenic agent, is investigated for its potential to enhance chemotherapy efficacy.

Purpose of the Study:

• To assess the efficacy and safety of bevacizumab combined with first-line oxaliplatin-based chemotherapy in MCRC patients.
• To compare two oxaliplatin-based regimens: capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4).
• To evaluate the impact of bevacizumab versus placebo on progression-free survival (PFS) and overall survival (OS).

Main Methods:

• A randomized, 2 × 2 factorial design trial involving 1,401 patients with MCRC.
• Patients were assigned to either XELOX or FOLFOX-4, and concurrently to bevacizumab or placebo.
• Progression-free survival (PFS) was the primary endpoint; overall survival (OS) and response rates were secondary endpoints.

Main Results:

• Median PFS was significantly improved with bevacizumab (9.4 months) compared to placebo (8.0 months) (HR, 0.83; P = .0023).
• Median OS showed a trend towards improvement with bevacizumab (21.3 months) versus placebo (19.9 months), but did not reach statistical significance (P = .077).
• Response rates were similar between bevacizumab and placebo groups; toxicity profiles were consistent with prior studies.

Conclusions:

• Bevacizumab addition to first-line oxaliplatin-based chemotherapy significantly enhances PFS in MCRC patients.
• While OS and response rates did not show statistically significant improvements, bevacizumab demonstrates a benefit in PFS.
• Optimizing treatment duration, particularly continuation until disease progression, may be crucial for maximizing bevacizumab's therapeutic contribution.